Compliance Pills

FDA approves pill with sensor that digitally tracks if patients have ingested their medication

Rumble (Mirror) | Telegram

November 13, 2017

The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.

The system works by sending a message from the pill’s sensor to a wearable patch. The patch transmits the information to a mobile application so that patients can track the ingestion of the medication on their smart phone. Patients can also permit their caregivers and physician to access the information through a web-based portal.

“Being able to track ingestion of medications prescribed for mental illness may be useful for some patients,” said Mitchell Mathis, M.D., director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “The FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers.”

It is important to note that Abilify MyCite’s prescribing information (labeling) notes that the ability of the product to improve patient compliance with their treatment regimen has not been shown. Abilify MyCite should not be used to track drug ingestion in “real-time” or during an emergency because detection may be delayed or may not occur. 

Schizophrenia is a chronic, severe and disabling brain disorder. About 1 percent of Americans have this illness. Typically, symptoms are first seen in adults younger than 30 years of age. Symptoms of those with schizophrenia include hearing voices, believing other people are reading their minds or controlling their thoughts, and being suspicious or withdrawn. Bipolar disorder, also known as manic-depressive illness, is another brain disorder that causes unusual shifts in mood, energy, activity levels and the ability to carry out day-to-day tasks. The symptoms of bipolar disorder include alternating periods of depression and high or irritable mood, increased activity and restlessness, racing thoughts, talking fast, impulsive behavior and a decreased need for sleep.

Abilify MyCite contains a Boxed Warning alerting health care professionals that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify MyCite is not approved to treat patients with dementia-related psychosis. The Boxed Warning also warns about an increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants. The safety and effectiveness of Abilify MyCite have not been established in pediatric patients. Patients should be monitored for worsening and emergence of suicidal thoughts and behaviors. Abilify MyCite must be dispensed with a patient Medication Guide that describes important information about the drug’s uses and risks.

In the clinical trials for Abilify, the most common side effects reported by adults taking Abilify were nausea, vomiting, constipation, headache, dizziness, uncontrollable limb and body movements (akathisia), anxiety, insomnia, and restlessness. Skin irritation at the site of the MyCite patch placement may occur in some patients.

I HOPE YOU DIDNT MISS THAT…

Boxed Warning for “Increased Risk of Death and Suicidal Thoughts”

“uncontrollable limb and body movements”

WAS LISTED AMONGST THE MOST COMMON SIDE EFFECTS IN THE CLINICAL TRIALS.

Prior to initial patient use of the product, the patient’s health care professional should facilitate use of the drug, patch and app to ensure the patient is capable and willing to use the system.

Abilify was first approved by the FDA in 2002 to treat schizophrenia. The ingestible sensor used in Abilify MyCite was first permitted for marketing by the FDA in 2012.

The FDA granted the approval of Abilify MyCite to Otsuka Pharmaceutical Co., Ltd. The sensor technology and patch are made by Proteus Digital Health.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

• FDA approves pill with sensor that digitally tracks if patients have ingested their medication ^{^01}
• Archive Copy: https://archive.ph/RbWaT
• Link to FDA Files: https://t.me/c19Videos/237
• This Video Clip: https://t.me/c19Videos/238
• Screenshots & PDF Copy of FDA Blackbox warnings https://t.me/c19Videos/239

Pfizer CEO Albert Bourla new bio-chip “Compliance ” pill

Rumble (Mirror) | Download on Telegram

“Imagine the Compliance” says Pfizer CEO Albert Bourla at WEF/DAVOS 2018 on his new “pill with tiny biological-chip that once it hits the stomach acid sends wireless signal to ‘relevant authorities’ …

Maybe this section is the reason I didn’t publish this post a few months ago, maybe I didn’t want to jump to conclusions about Pfizer’s Paxlovid pill after seeing how jolly-excited the Pfizer CEO was about the “digital compliance pills”…

Nothing further has come of this as far as I know (although noone in my personal life is hypnotized enough to get Paxlovid so I can’t scrutinize whether they have mastered the ability to make their guinea pigs even more compliant) …

Still, why ANYONE in the WORLD would trust this evil corporation‘s experimental PILL that only has Emergency Use Approval with zero consequences to any damage, zero benefit, makes you “sick again” which they’ve marketed as “REBOUND” (instead of “USELESS” “RISKY” “DANGEROUS” “EXPENSIVE” — seriously, they are totally fucking with us!) and opens you up to playing russian roulette with insidious global population ‘experiments’ is beyond sensical… defies all logic – please stop complying to tyranny and stop falling for the media-fear-porn funded by pharma & globalist agendas. It’s been 3 years now, and it’s so obvious and clear to see through multiple globalist agenda’s, and the information you need to return to common sense is collated in every language and country in the world – your natural bullshit radar should be raging by now.

…. “but Penny, what would I do if I got sick”… “seriously? are you living under a rock?”. Step one: Delete Mainstream Media. Step two: Avoid Google. Step three: Stay away from the New World Order. Step four: Realize you’ve been lied to and start doing research – no excuses now, just none.

Clinical criteria for PBS listed Lagevrio and Paxlovid:

• People 65 years or older with two additional high-risk factors for developing severe disease,
• People 75 years or older with one additional high-risk factor for developing severe disease,
• Moderately to severely immunocompromised people irrespective of vaccination status, and
• Aboriginal and Torres Strait Islander people aged 50 years or older with two additional high-risk factors for developing severe disease.

Priority communities

Initial distribution of the oral treatments by the Australian Government was prioritised to those with the highest clinical need including:

• people living in residential aged care facilities
• rural and remote communities
• Aboriginal and Torres Strait Islander people
• people with a disability, especially in a supported living setting.

• Antiviral treatments for COVID-19 – NPS.org.au ^{^02}
• Covid-19 pills: vulnerable and unvaccinated Australians to be prioritised for new oral treatments – The Guardian ^{^03}
• Oral treatments for COVID-19 – Health.gov.au ^{^04}
• Lagevrio^® (molnupiravir) PBS listing – PBS.gov.au ^{^05}
• Paxlovid^® (nirmatrelvir and ritonavir) PBS listing – PBS.gov.au ^{^06}

Google DARPA | Compliance / Authentication Pills, Tattoos, & Edible Passwords (2013) – Full Version

Rumble (Mirror) | YouTube (Official) | Download on Telegram

Regina Dugan at D11 2013
1 Jun 2013 Google’s Regina Dugan shows off electronic tattoos and edible passwords at D11 conference.

Psychiatry was captured completely by the drug companies in the 1950s says Dr Peter Breggin. He says the powers that be are obsessed with control of the human mind, keeping people docile.

• Watch interview | Psychiatrist & Author of “Covid-19 and the Global Predators. We are the prey.“

• Graphene-Based Sensors for Human Health Monitoring ^{^07}

Abstract: Since the desire for real-time human health monitoring as well as seamless human-machine interaction is increasing rapidly, plenty of research efforts have been made to investigate wearable sensors and implantable devices in recent years. As a novel 2D material, graphene has aroused a boom in the field of sensor research around the world due to its advantages in mechanical, thermal, and electrical properties. Numerous graphene-based sensors used for human health monitoring have been reported, including wearable sensors, as well as implantable devices, which can realize the real-time measurement of body temperature, heart rate, pulse oxygenation, respiration rate, blood pressure, blood glucose, electrocardiogram signal, electromyogram signal, and electroencephalograph signal, etc. Herein, as a review of the latest graphene-based sensors for health monitoring, their novel structures, sensing mechanisms, technological innovations, components for sensor systems and potential challenges will be discussed and outlined.

PMCID: PMC6580932

• Flexible and Stretchable Physical Sensor Integrated Platforms for Wearable Human-Activity Monitoring and Personal Healthcare ^{^08}
• 3D-Printed Graphene/Polydimethylsiloxane Composites for Stretchable and Strain-Insensitive Temperature Sensors ^{^09}
• (Heart-Monitor) A Wearable and Highly Sensitive Graphene Strain Sensor for Precise Home-Based Pulse Wave Monitoring ^{^10}
• Highly Elastic Graphene-Based Electronics Toward Electronic Skin ^{^11}
• Three dimensional graphene scaffold for cardiac tissue engineering and in-situ electrical recording ^{^12}
• (Glucose Monitoring) A flexible enzyme-electrode sensor with cylindrical working electrode modified with a 3D nanostructure for implantable continuous glucose monitoring ^{^13}
• Flexible, Highly Sensitive, and Wearable Pressure and Strain Sensors with Graphene Porous Network Structure ^{^14}
• Highly stretchable strain sensors with reduced graphene oxide sensing liquids for wearable electronics ^{^15}
• (Bodily Motion-Sensors) Sensitive, high-strain, high-rate bodily motion sensors based on graphene-rubber composites ^{^16}
• Epidermis Microstructure Inspired Graphene Pressure Sensor with Random Distributed Spinosum for High Sensitivity and Large Linearity ^{^17}
• (Brain) Considerations for Safe Innovation: The Case of Graphene ^{^18}
• (Eyes) Wearable smart sensor systems integrated on soft contact lenses for wireless ocular diagnostics ^{^19}
• The rise of plastic bioelectronics ^{^20}